In vitro-in vivo relationship of oral extended-release dosage forms.
OBJECTIVE
A method to establish the in vitro-in vivo relationship of oral extended-release products is proposed.


METHODS
The approach utilizes incremental amounts of drug released and absorbed within defined time intervals, to construct a chi2 distributed variable for testing in vitro-in vivo similarity.


RESULTS
A case study is used to demonstrate that the similarities between incremental values of in vivo absorbed and in vivo dissolved fractions are distinguishable for different dissolution profiles despite naturally significant linear correlations between cumulative in vivo absorbed and in vitro dissolved fractions (with different dissolution tests) of an oral extended-release product.


CONCLUSIONS
The method enables investigators to compare different in vitro dissolution profiles of an oral extended-release product to find an optimized dissolution profile to be the surrogate of the in vivo release process of the product.
Impax Pharmaceuticals, Fremont, California 94539, USA.
F Y
FY
Liu
N C
NC
Sambol
R P
RP
Giannini
C Y
CY
Liu
D000042:Absorption; D000284:Administration, Oral; D003692:Delayed-Action Preparations; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D008432:Mathematical Computing; D008722:Methods; D010599:Pharmacokinetics; D012995:Solubility
D003692:Delayed-Action Preparations